Levacetylleucine and Apixaban: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Apixaban
Levacetylleucine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What's going on: Apixaban (Eliquis) is a blood thinner. Your body normally pumps some of it back out using a transporter called P-gp. Levacetylleucine (Aqneursa) can slow that pump down, so a bit more apixaban may stay in your body. That could make the blood-thinning effect a little stronger and slightly raise the chance of bruising or bleeding.
Good news: This is based on how the drugs work in theory, not on lots of real-world reports. Keep taking both exactly as prescribed. Just watch for easy bruising, nosebleeds, or unusual bleeding, and let your pharmacist or doctor know so they can keep an eye on you.
Mechanism: Levacetylleucine inhibits P-gp-mediated efflux. Apixaban is a P-gp substrate, so inhibition may increase apixaban exposure (AUC/Cmax) and raise bleeding risk. Neither agent is a prodrug; direction is increased substrate effect.
- Direction: Increased apixaban exposure and anticoagulant effect.
- Magnitude: Not quantified.
- Onset: Unspecified.
- Evidence: Theoretical.
- Management: Monitor more frequently for bleeding (bruising, mucosal bleeding, drops in hemoglobin). Dose may be individualized by the care team; consider clinical vigilance during concomitant use.
What happens
Increased P-gp inhibitor exposure and an increased risk of P-gp substrate-related adverse reactions
Interaction Deep Dive
Taking levacetylleucine together with P-gp substrates can raise the exposure to those P-gp substrates and heighten the likelihood of adverse reactions associated with them. When levacetylleucine is given concurrently, increase the frequency of monitoring for adverse reactions related to the P-gp substrate1.
Why it happens (mechanism)
Inhibition of P-gp-mediated efflux transport by levacetylleucine
How to manage this interaction
Keep taking both apixaban and levacetylleucine as prescribed unless your care team tells you otherwise.
- Closer monitoring: Your team may watch more closely for signs that the blood thinner is acting more strongly.
- Watch for: Unusual bruising, nosebleeds, bleeding gums, pink or red urine, black stools, or bleeding that won't stop.
- Dosing: If needed, your apixaban dose can be adjusted and individualized by your care team.
- Speak up: Tell your pharmacist or prescriber that you take both, and report any bleeding promptly.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Levacetylleucine and Apixaban together?
Levacetylleucine may modestly increase apixaban levels and bleeding risk, so keep taking both as prescribed and watch for unusual bruising or bleeding. This concern is theoretical, and your care team can manage it with monitoring. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Levacetylleucine and Apixaban interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Levacetylleucine and Apixaban interaction managed?
Keep taking both apixaban and levacetylleucine as prescribed unless your care team tells you otherwise. Closer monitoring: Your team may watch more closely for signs that the blood thinner is acting more strongly. Watch for: Unusual bruising, nosebleeds, bleeding gums, pink or red urine, black stools, or bleeding that won't stop. Dosing: If needed, your apixaban dose can be adjusted and individual… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Levacetylleucine or Apixaban need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (1)
- Product Information: AQNEURSA(TM) oral suspension, levacetylleucine oral suspension. IntraBio Inc. (per FDA), Austin, TX, 2024. DailyMed
Keep reading about Apixaban
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist